These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20920382)

  • 1. Maintaining high rates of measles immunization in Africa.
    Lessler J; Moss WJ; Lowther SA; Cummings DA
    Epidemiol Infect; 2011 Jul; 139(7):1039-49. PubMed ID: 20920382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey.
    Lowther SA; Curriero FC; Kalish BT; Shields TM; Monze M; Moss WJ
    Lancet; 2009 Mar; 373(9668):1025-32. PubMed ID: 19211140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling measles using supplemental immunization activities: a mathematical model to inform optimal policy.
    Verguet S; Johri M; Morris SK; Gauvreau CL; Jha P; Jit M
    Vaccine; 2015 Mar; 33(10):1291-6. PubMed ID: 25541214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of measles supplementary immunization activities on reaching children missed by routine programs.
    Portnoy A; Jit M; Helleringer S; Verguet S
    Vaccine; 2018 Jan; 36(1):170-178. PubMed ID: 29174680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in measles control--Zambia, 1999-2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Jun; 54(23):581-4. PubMed ID: 15959454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in global measles control, 2000-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(4):73-8. PubMed ID: 22298303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of disruptions to routine vaccination programs, quantifying burden of measles, and mapping targeted supplementary immunization activities.
    Kostandova N; Loisate S; Winter A; Moss WJ; Giles JR; Metcalf CJE; Mutembo S; Wesolowski A
    Epidemics; 2022 Dec; 41():100647. PubMed ID: 36343498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles supplemental immunization activities improve measles vaccine coverage and equity: Evidence from Kenya, 2002.
    Vijayaraghavan M; Martin RM; Sangrujee N; Kimani GN; Oyombe S; Kalu A; Runyago A; Wanjau G; Cairns L; Muchiri SN
    Health Policy; 2007 Sep; 83(1):27-36. PubMed ID: 17174435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International measles incidence and immunization coverage.
    Hall R; Jolley D
    J Infect Dis; 2011 Jul; 204 Suppl 1():S158-63. PubMed ID: 21666157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles control in Sub-Saharan Africa: South Africa as a case study.
    Verguet S; Jassat W; Hedberg C; Tollman S; Jamison DT; Hofman KJ
    Vaccine; 2012 Feb; 30(9):1594-600. PubMed ID: 22230581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
    Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward measles elimination in the People's Republic of China, 2000-2009.
    Ma C; An Z; Hao L; Cairns KL; Zhang Y; Ma J; Cao L; Wen N; Xu W; Liang X; Yang W; Luo H
    J Infect Dis; 2011 Jul; 204 Suppl 1():S447-54. PubMed ID: 21666198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health effects of routine measles vaccination and supplementary immunisation activities in 14 high-burden countries: a Dynamic Measles Immunization Calculation Engine (DynaMICE) modelling study.
    Auzenbergs M; Fu H; Abbas K; Procter SR; Cutts FT; Jit M
    Lancet Glob Health; 2023 Aug; 11(8):e1194-e1204. PubMed ID: 37474227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles incidence before and after supplementary vaccination activities--Lusaka, Zambia, 1996-2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Jun; 50(24):513-6. PubMed ID: 11432675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population immunity to measles in the United States, 1999.
    Hutchins SS; Bellini WJ; Coronado V; Jiles R; Wooten K; Deladisma A
    J Infect Dis; 2004 May; 189 Suppl 1():S91-7. PubMed ID: 15106096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.